Physician profile
James B Cooper
NPI 1356436745
$199,790.33
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $43K · 2021: $62K · 2022: $32K · 2023: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $67,751.98 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $44,594.20 | 2019-2023 | Austedo, Ajovy |
| Abbvie INC. | $43,917.30 | 2021-2023 | Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $15,888.65 | 2020-2021 | |
| Allergan, INC. | $14,578.01 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $4,212.03 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,592.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $734.80 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $556.96 | 2019-2023 | Rytary |
| Genzyme Corporation | $546.59 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $528.25 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $300.25 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $279.62 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $267.48 | 2019-2022 | |
| Assertio Therapeutics, INC. | $253.85 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.